Conexeu Sciences Inc.

What Conexeu Sciences Inc. does

Conexeu Sciences Inc. is a preclinical-stage biotechnology company developing a patented collagen-based bioregenerative extracellular matrix (ECM) platform branded CXU™. The core technology is a thermosensitive scaffold that remains flowable at room temperature and transitions to a stable gel at body temperature within approximately ten minutes. The lead device candidate, Ten Minute Tissue™, targets advanced wound care indications including post-Mohs defects, burns, dehiscent wounds, and tunneling wounds, with a planned FDA 510(k) submission targeted for Q1 2027. The same CXU™ foundation supports a secondary program — B.R.E.A.S.T.™, a 3D-bioprinted bioregenerative breast matrix developed in partnership with the Wake Forest Institute for Regenerative Medicine using the iTOPS bioprinting system — plus pipeline applications in medical aesthetics (facial rejuvenation, GLP-1-driven skin laxity, body contouring), oral health/periodontal regeneration, animal health/veterinary medicine, and 3D bioprinting/biofabrication, all under a single formulation strategy intended to avoid reformulation across indications.

The company is pre-revenue. Form C (July 2025) and Form D filings report $0 in sales and a $471,867 net loss in the most recent fiscal year, against $533,940 in total assets and $314,616 in cash. Capital to date has been raised through equity: a $1.29M Rule 506(b) private placement (Form D, April 2025), a $5.0M Regulation Crowdfunding round closed October 2025 via Equifund, ~$3.12M in two further Rule 506(b) placements (Form D, November 2025), and a Nasdaq IPO on May 21, 2026 under ticker CNXU (~25.27M shares issued, 35.24M fully diluted). Future revenue is expected to come from unit sales of 510(k)-cleared medical devices to hospitals, plastic surgeons, dermatologists, wound-care clinics, and through licensing/channel partnerships into aesthetics and veterinary end markets, with no product revenue currently recognized.

Conexeu is headquartered in Reno, Nevada, operates a research and development facility at adMare BioInnovations' M4 Innovation Centre in Vancouver, British Columbia (opened June 23, 2026), and runs a preclinical development program at the Wake Forest Institute for Regenerative Medicine in Winston-Salem, North Carolina. The leadership team is anchored by President & CEO Miles Harrison (formerly Galderma North America President and part of the executive team behind Galderma's $10.2B Nestle-to-EQT divestiture), co-founders David Bogart (Chief Commercial Officer) and Dr. Claudia Chavez-Munoz (Chief Scientific Officer, 40+ peer-reviewed publications, PhD in Experimental Medicine from UBC), Chief Medical Officer Dr. Brian Pilcher (ex-Merz, ex-Suneva), Chief Financial Officer Steve Inouye, and a nine-person Board of Directors expanded in June 2026 with the appointments of Ana Bastiani-Posner, April Burke, and Andrew Costa.

Name

Conexeu Sciences Inc.

Legal name

Conexeu Sciences Inc.

Website

https://conexeu.com

Company type

Public

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

Conexeu Sciences is a preclinical-stage biotech developing a patented CXU™ collagen-based bioregenerative ECM platform, with lead device Ten Minute Tissue™ targeting advanced wound care (FDA 510(k) target Q1 2027) and pipeline applications across aesthetics, breast reconstruction, oral health, veterinary, and 3D bioprinting; recently IPO'd on Nasdaq (CNXU).

Ownership category

akta.pro rank

Product category

Regenerative Medicine Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)

akta.pro secondary industries

Acellular/Decellularized Matrices & ECM Products (HLAAAGAF), Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), 3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial) (HLAHAEAJ), Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware) (IMAAAAAG)

Keywords

• Regenerative medicine devices
• Collagen extracellular matrix
• Wound care scaffolds
• Bioprinting medical devices
• Aesthetic injectables platform

Headquarters

HQ city

Reno

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Preclinical / Pre-Revenue: Conexeu is preclinical-stage and pre-revenue. Form D filed May 2025 and Form C offering statement filed July 2025 both report $0 revenue/sales, $0 cost of goods sold, and a net loss of $471,867 in the most recent fiscal year. No commercial product revenue is recognized.
2. Future Medical Device Sales (planned): Planned future revenue from sales of Ten Minute Tissue™ and pipeline CXU-based medical devices (wound care, aesthetics, oral health, breast reconstruction) following FDA 510(k) clearance targeted for early 2027. Future model expected to be device unit sales to hospitals, plastic surgeons, dermatologists, and clinics.
3. Equity Capital Raises (current): Current funding mechanism: Regulation Crowdfunding (Reg CF) raises via Equifund ($5M closed October 2025), Rule 506(b) private placements (Form D filings in 2025 and 2026), and Nasdaq IPO listing in May 2026 under ticker CNXU. Equity-based funding is the primary cash inflow pre-commercialization.

Pricing tiers

Go-to-market motion4 records

Marketing channels8 records

Core offering

Conexeu Sciences is developing the CXU™ bioregenerative extracellular matrix (ECM) platform, a patented collagen-based, thermosensitive scaffold that remains flowable at room temperature and transitions into a stable gel at body temperature within approximately ten minutes. The lead device candidate, Ten Minute Tissue™, is a CXU-based injectable ECM targeting advanced wound care indications (post-Mohs defects, burns, dehiscent wounds, tunneling wounds) with a planned FDA 510(k) submission in Q1 2027. The B.R.E.A.S.T.™ 3D-bioprinted breast matrix, developed with Wake Forest Institute for Regenerative Medicine using the iTOPS platform, extends the same CXU foundation into bioregenerative breast reconstruction.

Product overview

Conexeu Sciences Inc. offers a single unified investigational medical-device platform — the patented CXU™ bioregenerative extracellular matrix (ECM) technology — built on one collagen-based structural principle (one formula, one device) and applied across multiple addressable indications without reformulation. The platform's lead device candidate, Ten-Minute Tissue™ (an injectable ECM that gels at body temperature in approximately ten minutes), anchors the wound-care program and is targeted for an FDA 510(k) submission in early 2027; its secondary candidate, B.R.E.A.S.T.™ (a 3D-bioprinted bioregenerative breast matrix developed in partnership with WFIRM using the iTOPS system), extends the platform into breast reconstruction. The same CXU™ foundation powers additional application areas spanning Aesthetics (regenerative injectables, facial rejuvenation, body contouring, GLP-1-driven skin laxity), Oral Health (periodontal), Animal Health (veterinary), and 3D Bioprinting / Biofabrication, making the company's commercial strategy a platform-plus-multiple-indication architecture rather than a portfolio of unrelated products.

Differentiator

Problem solved

Functional benefit

Brands

• CXU™: Proprietary collagen-based extracellular matrix (ECM) medical device candidate / bioregenerative tissue platform designed to support tissue regeneration across wound care, aesthetics, oral health, animal health, and 3D bioprinting applications.
• Ten Minute Tissue™
• B.R.E.A.S.T.™ (Bio-Regenerative Ergonomically Architected Smart Tissue™)

Products and services

• CXU™ Bioregenerative ECM Platform Patented collagen-based, thermosensitive extracellular matrix (ECM) scaffold medical device candidate designed as a single structural foundation that remains flowable at room temperature and transitions into a stable gel in situ at body temperature. Built on one formula and one device design intended to scale across wound care, medical aesthetics, oral health, animal health, and 3D bioprinting without reformulation. Supports the three phases of tissue regeneration (Repopulate, Remodel, Regenerate).
• Ten Minute Tissue™ Injectable ECM Device Candidate Lead CXU-based injectable extracellular matrix device candidate that remains fluid at room temperature and transitions to a stable gel in situ at body temperature within approximately ten minutes. Targets advanced wound care applications including post-Mohs defects, burns, dehiscent wounds, and tunneling wounds. Preclinical pilot studies showed approximately 2.5x faster healing versus industry devices.
• B.R.E.A.S.T.™ 3D-Bioprinted Bioregenerative Breast Matrix 3D-bioprinted bioregenerative breast matrix developed using the proprietary CXU™ extracellular matrix bioink and engineered as a resorbable, acellular, bioregenerative scaffold to guide the patient's own cells toward new tissue formation. Designed as an alternative to permanent breast implants for post-mastectomy reconstruction; preclinical program in partnership with WFIRM.

Quantifiable outcome

• Preclinical pilot studies showed approximately 2.5x faster healing compared to industry devices (Forbes D. et al., Journal of Burn Care & Research, 2019)
• +3 more outcomes

Segments6 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Scale indicators10 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• Organogenesis Holdings: Commercial-stage regenerative medicine company specializing in skin substitutes and wound care products (Apligraf, Dermagraft, PuraPly). Direct competitor to Conexeu's lead wound-care indication targeting post-Mohs defects, burns, dehiscent wounds and tunneling wounds with an ECM-based scaffold approach.
• MiMedx Group: Regenerative medicine company marketing amniotic membrane-based products (EpiFix, AmnioFix, Axiofill) for wound care and surgical recovery. Closely comparable to Conexeu in targeting advanced wound healing with a biologic ECM-like scaffold sold into hospitals and wound care clinics.
• Integra LifeSciences: Established regenerative technologies company with a broad portfolio of wound care, dural repair, and collagen-based scaffolds (Integra Dermal Regeneration Template). Most directly comparable to Conexeu on the collagen/ECM scaffold architecture and wound-care end market.
• Vericel Corporation: Specialty regenerative medicine company commercializing cell-therapy and ECM-based products for severe burns (Epicel) and cartilage repair (MACI). A direct comparable in the advanced wound-care and regenerative-medicine category that Conexeu is targeting with Ten Minute Tissue™.
• Establishment Labs: Aesthetic and reconstructive breast implant company (Motiva) with a focus on next-generation implant technology and breast aesthetics/reconstruction. Most directly comparable to Conexeu's B.R.E.A.S.T.™ 3D-bioprinted bioregenerative breast matrix program targeting the same post-mastectomy reconstruction market.

Broad incumbents

• Smith+Nephew: Global medical devices company with a large Advanced Wound Management portfolio including skin substitutes and negative-pressure wound therapy. Named by Conexeu as a competitor in wound care; represents a well-capitalized incumbent against which Conexeu's lead 510(k) program will compete for hospital formulary access.
• Coloplast: Global Danish medical device company with a sizeable Wound & Skin Care business (Biatain, Hydrocolloid dressings) and an established hospital sales channel. Listed by Conexeu among wound-care competitors and a broad incumbent that Conexeu's regenerative ECM approach would compete against on efficacy and total cost of care.
• Galderma: Global dermatology/aesthetics leader (Sculptra, Restylane, Dysport, Cetaphil) sold by Nestle to EQT for $10.2B. The dominant incumbent in the injectable aesthetics category Conexeu's CXU™ aesthetics application would enter; multiple Conexeu executives (CEO, CCO, Head of BD, Head of Strategy) are ex-Galderma.
• Merz Aesthetics: Global aesthetics player behind Radiesse, Belotero, Xeomin and Ultherapy. Conexeu's CMO Dr. Brian Pilcher was VP Medical Affairs at Merz North America; direct incumbent competitor in the aesthetic injectables category Conexeu is targeting as a bioregenerative alternative.

Emerging players

• Evolus: Aesthetic injectables company focused on next-generation neurotoxins (Jeuveau) competing with Allergan's Botox. Comparable as an emerging aesthetics player building market share against Galderma and Merz in the same physician-channel that Conexeu's aesthetics program intends to enter.

Market position

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/conexeu-sciences-inc
• Instagraminstagram.com/conexeusciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds4 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Conexeu Sciences Inc.